Evidence map›Paper›PMID 30983488›Full record

ArticleCancer biology & therapy2019

Knockdown of lncRNA LEF1-AS1 inhibited the progression of oral squamous cell carcinoma (OSCC) via Hippo signaling pathway.

Chanqiong Zhang, Chunchun Bao, Xiuxing Zhang, Xinshi Lin, Dan Pan, Yangzong Chen

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Chanqiong ZhangDepartment of Pathology, Wenzhou People's Hospital , Wenzhou , Zhejiang , China.
Chunchun BaoDivision of PET/CT, Department of Radiology, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou , Zhejiang , China.
Xiuxing ZhangDivision of PET/CT, Department of Radiology, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou , Zhejiang , China.
Xinshi LinDivision of PET/CT, Department of Radiology, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou , Zhejiang , China.
Dan PanDepartment of Pathology, Wenzhou People's Hospital , Wenzhou , Zhejiang , China.
Yangzong ChenDivision of PET/CT, Department of Radiology, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou , Zhejiang , China.
First Affiliated Hospital of Wenzhou Medical University · CNWenzhou City People's Hospital · CNWenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is verified that long non-coding RNAs (lncRNAs) play crucial roles in various cancers. LncRNA LEF1-AS1 is a reported oncogene in colorectal cancer and glioblastoma. In this study, we unveiled that LEF1-AS1 markedly increased in oral squamous cell carcinoma (OSCC) tissues and cell lines. Besides, OSCC patients with high levels of LEF1-AS1 were apt to poor prognosis. Functionally, LEF1-AS1 knockdown inhibited cell survival, proliferation and migration, whereas enhanced cell apoptosis and induced G0/G1 cell cycle arrest in vitro. Consistently, LEF1-AS1 silence hindered tumor growth in vivo. Moreover, LEF1-AS1 inhibition stimulated the activation of Hippo signaling pathway through directly interacting with LATS1. Furtherly, we disclosed that LEF1-AS1 silence abolished the interaction of LEF1-AS1 with LATS1 while enhanced the binding of LATS1 to MOB, therefore promoting YAP phosphorylation but impairing YAP1 nuclear translocation. Additionally, we demonstrated that LEF1-AS1 regulated YAP1 translocation via a LATS1-dependent manner. Furthermore, we also uncovered that YAP1 overexpression abolished the suppressive impact of LEF1-AS1 repression on the biological processes of OSCC cells. In a word, we concluded that LEF1-AS1 served an oncogenic part in OSCC through suppressing Hippo signaling pathway by interacting with LATS1, suggesting the therapeutic and prognostic potential of LEF1-AS1 in OSCC.

Indexed as

Signal TransductionAdultAgedAnimalsCarcinoma, Squamous CellCell Cycle CheckpointsCell Line, TumorDisease ProgressionFemaleGene Knockdown TechniquesHeterograftsHippo Signaling PathwayHumansLymphoid Enhancer-Binding Factor 1MaleMiceLEF1 protein, humanLymphoid Enhancer-Binding Factor 1Protein Serine-Threonine KinasesRNA, Long NoncodingHippo pathwayLATS1LEF1-AS1OSCC progression

Identifiers

PMID30983488
PMCPMC6741770
OpenAlexW2939767289

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.